Rabies immunoglobulin
Brand names: HyperRAB, Imogam
Rabies immunoglobulin is a preparation of antibodies against rabies virus used as part of post-exposure prophylaxis to provide immediate passive immunity following a high-risk rabies exposure in previously unvaccinated individuals.
Vaccines and immunoglobulins are given by national schedule or product-specific guidance: see the UK Green Book (UKHSA) and the product's SmPC.
Clinical monograph
How it works
It supplies ready-made neutralising antibodies that bind and inactivate rabies virus at the wound site during the interval before an active immune response to vaccine develops.
Prescribing in practice
- As much of the dose as possible should be infiltrated into and around the wound, with any remainder given intramuscularly at a site distant from the vaccine to avoid neutralising the vaccine response.
- It is given together with, but never mixed in the same syringe as, rabies vaccine as part of post-exposure prophylaxis.
- It is indicated only for unimmunised (or incompletely immunised) people with a significant exposure; those previously fully vaccinated need vaccine boosters rather than immunoglobulin, as advised by specialist services.
Monitoring
Observe for immediate hypersensitivity reactions after administration; no routine laboratory monitoring is required.
Counselling the patient
- This injection gives immediate protection while the vaccine course builds your own immunity.
- Thorough wound cleaning and completing the full vaccine schedule are essential.
- Seek urgent specialist advice without delay after any possible rabies exposure.
Evidence & guidelines
Combined rabies immunoglobulin and vaccine for post-exposure prophylaxis is recommended by WHO and UK Health Security Agency guidance for high-risk exposures.
Reference: UKHSA Green Book Ch.27; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023